An EZH2-NF-κB Regulatory Axis Drives Expression of Pro-oncogenic Gene Signatures in Triple Negative Breast Cancer

Overview

Journal iScience

Publisher Cell Press

Date 2023 Jul 7

PMID 37416481

Authors

Gabrielle J Dardis

Jun Wang

Jeremy M Simon

Gang Greg Wang

Albert S Baldwin

Affiliations

Soon will be listed here.

Abstract

The histone methyltransferase EZH2 has been studied most extensively in the context of PRC2-dependent gene repression. Accumulating evidence indicates non-canonical functions for EZH2 in cancer contexts including promoting paradoxical gene expression through interactions with transcription factors, including NF-κB in triple negative breast cancer (TNBC). We profile EZH2 and NF-κB factor co-localization and positive gene regulation genome-wide, and define a subset of NF-κB targets and genes associated with oncogenic functions in TNBC that is enriched in patient datasets. We demonstrate interaction between EZH2 and RelA requiring the recently identified transactivation domain (TAD) which mediates EZH2 recruitment to, and activation of certain NF-κB-dependent genes, and supports downstream migration and stemness phenotypes in TNBC cells. Interestingly, EZH2-NF-κB positive regulation of genes and stemness does not require PRC2. This study provides new insight into pro-oncogenic regulatory functions for EZH2 in breast cancer through PRC2-independent, and NF-κB-dependent regulatory mechanisms.

Citing Articles

Reducing batch effects in single cell chromatin accessibility measurements by pooled transposition with MULTI-ATAC.

Conrad D, Phong K, Korotkevich E, McGinnis C, Zhu Q, Chow E bioRxiv. 2025; .

PMID: 40027737 PMC: 11870453. DOI: 10.1101/2025.02.14.638353.

Genetic variation in IL-4 activated tissue resident macrophages determines strain-specific synergistic responses to LPS epigenetically.

Zhao M, Jankovic D, Link V, Souza C, Hornick K, Oyesola O Nat Commun. 2025; 16(1):1030.

PMID: 39863579 PMC: 11762786. DOI: 10.1038/s41467-025-56379-8.

Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities.

Wozniak M, Czyz M Ther Adv Med Oncol. 2025; 17():17588359241306026.

PMID: 39776536 PMC: 11705335. DOI: 10.1177/17588359241306026.

Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma.

Lee J, You C, Kwon G, Noh J, Lee K, Kim K Cell Death Dis. 2024; 15(11):801.

PMID: 39516467 PMC: 11549485. DOI: 10.1038/s41419-024-07198-0.

DAB2IP loss in luminal a breast cancer leads to NF-κB-associated aggressive oncogenic phenotypes.

Mukherjee A, Kakati R, Van Alsten S, Laws T, Ebbs A, Hollern D JCI Insight. 2024; 9(23).

PMID: 39418101 PMC: 11623953. DOI: 10.1172/jci.insight.171705.

References

Xu J, Shao Z, Li D, Xie H, Kim W, Huang J . Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. Mol Cell. 2015; 57(2):304-316. PMC: 4305004. DOI: 10.1016/j.molcel.2014.12.009. View

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

Liao W, Yen H, Chen C, Chu Y, Song Y, Tseng T . CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. Am J Cancer Res. 2021; 11(3):812-826. PMC: 7994168. View

Anwar T, Gonzalez M, Kleer C . Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer. Am J Pathol. 2021; 191(5):774-783. PMC: 8127103. DOI: 10.1016/j.ajpath.2021.01.013. View

Kim J, Lee Y, Lu X, Song B, Fong K, Cao Q . Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Rep. 2018; 25(10):2808-2820.e4. PMC: 6342284. DOI: 10.1016/j.celrep.2018.11.035. View

Souroullas G, Jeck W, Parker J, Simon J, Liu J, Paulk J . An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med. 2016; 22(6):632-40. PMC: 4899144. DOI: 10.1038/nm.4092. View

Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y . Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 2009; 100(9):1668-74. PMC: 11158550. DOI: 10.1111/j.1349-7006.2009.01228.x. View

Lawrence C, Baldwin A . Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer. PLoS One. 2016; 11(10):e0165005. PMC: 5072726. DOI: 10.1371/journal.pone.0165005. View

Rueda O, Sammut S, Seoane J, Chin S, Caswell-Jin J, Callari M . Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019; 567(7748):399-404. PMC: 6647838. DOI: 10.1038/s41586-019-1007-8. View

10.

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

11.

Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T . TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling. Int J Mol Sci. 2017; 18(9). PMC: 5618580. DOI: 10.3390/ijms18091931. View

12.

Espinoza I, Kurapaty C, Park C, Steen T, Kleer C, Wiley E . Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness. Am J Cancer Res. 2022; 12(2):839-851. PMC: 8899977. View

13.

Onyeisi J, Lopes C, Gotte M . Role of syndecan-4 in breast cancer pathophysiology. Am J Physiol Cell Physiol. 2022; 323(5):C1345-C1354. DOI: 10.1152/ajpcell.00152.2022. View

14.

Garapaty-Rao S, Nasveschuk C, Gagnon A, Chan E, Sandy P, Busby J . Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol. 2013; 20(11):1329-39. DOI: 10.1016/j.chembiol.2013.09.013. View

15.

Pereira B, Chin S, Rueda O, Vollan H, Provenzano E, Bardwell H . The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016; 7:11479. PMC: 4866047. DOI: 10.1038/ncomms11479. View

16.

Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P . Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298(5595):1039-43. DOI: 10.1126/science.1076997. View

17.

Baldwin Jr A, Azizkhan J, Jensen D, Beg A, Coodly L . Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol Cell Biol. 1991; 11(10):4943-51. PMC: 361472. DOI: 10.1128/mcb.11.10.4943-4951.1991. View

18.

McCabe M, Ott H, Ganji G, Korenchuk S, Thompson C, Van Aller G . EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-12. DOI: 10.1038/nature11606. View

19.

Xu B, On D, Ma A, Parton T, Konze K, Pattenden S . Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2014; 125(2):346-57. PMC: 4287641. DOI: 10.1182/blood-2014-06-581082. View

20.

Potjewyd F, Turner A, Beri J, Rectenwald J, Norris-Drouin J, Cholensky S . Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader. Cell Chem Biol. 2019; 27(1):47-56.e15. PMC: 7004250. DOI: 10.1016/j.chembiol.2019.11.006. View